SCHEMBL16355447

SCHEMBL16355447

CN[C@H](C)c1ncc(-c2ccc(C)cc2)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CDK5R1 Q15078 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
SMPD3 Q9NY59 1/20 0.40
SSTR3 P32745 3/20 0.39
ABL1 P00519 1/20 0.39
RET P07949 1/20 0.39
KDR P35968 1/20 0.39
CDK7 P50613 1/20 0.39
PRKAA1 Q13131 1/20 0.39
AURKB Q96GD4 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12158461 0.92 NPC1 (0.37)
SCHEMBL16355449 0.86 PTGES (0.43) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL16355444 0.86 PTGES (0.43) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL16355442 0.86 SCN10A (0.36)
SCHEMBL11965519 0.83 MEN1 (0.43) CDK5CCNB2CDK1CCNB1GSK3A
SCHEMBL12107457 0.82 NLN (0.41) GSK3B
SCHEMBL14300085 0.82 NPC1 (0.34)
SCHEMBL14274103 0.82 SCN5A (0.34)
SCHEMBL16355456 0.81 CYP1A1 (0.37) CYP1A2
SCHEMBL16355448 0.80 SCN10A (0.41) CDK5CCNB2CDK1CCNB1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1L, HBS1L, HAVCR2 CDK5 1552/4885CCNB2 472/4885CDK1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.